Definitive Contract 75N93024C00022
Award Date
9/30/24
Potential Completion Date
9/29/29
Potential Value
$11M
Federal Agency
National Institute of Allergy and Infectious Diseases
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost No Fee
Place of Performance
La Jolla, CA 92037, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
13
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The University of California, San Diego (UCSD) was awarded a $10,223,791 Definitive Federal Contract by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) to identify novel adjuvant candidates that can be used to augment the efficacy of human vaccines. This contract does not have a set-aside designation. As part of this effort, UCSD has issued subcontracts to several companies, including Life Technologies Corporation, Inimmune Corp,...
The University of California, San Diego was awarded a definitive cost-no-fee contract from the National Institutes of Health's National Institute of Allergy and Infectious Diseases totaling $12.7 million to support the Adjuvant Discovery Program. The prime contractor, UC San Diego, will work with several notable subcontractors including Inimmune Corp, Miltenyi Biotec, Repertoire Genesis, Life Technologies Corporation, Icahn School of Medicine at Mount Sinai, and Agilent Technologies over the...
This is a $9,807,060 definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), to the University of Chicago. The contract is for the Vaccine Adjuvant Discovery Program (VADP), which aims to evaluate and develop animal and animal replacement models for screening and assessing candidate countermeasures such as therapeutics, vaccines, and diagnostics. This contract is not set-aside and is a cost-type...
This federal contract award, valued at $8,762,844.00, was made by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH) within the Department of Health and Human Services (DHHS). The contract was awarded to the University of California, Irvine (UC Irvine) to conduct a research program comparing multiple vaccine adjuvants across various platforms. The goal is to establish immunological profiles of the adjuvants' strength,...
This federal contract award for $18,472,563.99 was issued by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to the University of Montana. The contract's objective is to identify novel adjuvant candidates that can be used to augment the efficacy of human vaccines. Research under this definitive, cost-no-fee contract will contribute to the pipeline of new adjuvant leads that either exploit the innate immune system or act directly...
The National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, has awarded a $4,532,373.05 firm fixed-price contract to the University of California San Diego (UCSD) Scripps Institution of Oceanography. The contract, which does not have a set-aside designation, is for the development of a small-molecule dual adjuvant system for influenza virus vaccine. Scripps Institution of Oceanography, a division of UCSD, is a world-renowned center for ocean and earth science research...
This is a $10,172,188 definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency under the Department of Health and Human Services, to the University of Montana for a Vaccine Adjuvant Discovery Program. The contract involves research to identify and characterize novel, effective, and safe vaccine adjuvants, including high-throughput screening, mechanism of action studies, lead compound optimization, and in vivo efficacy testing. The...
This is a $5,822,726 definitive federal contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health, to Duke University for a project titled "ADJUVANT COMPARISON AND CHARACTERIZATION". The contract is for a 4-year period ending on June 30, 2026 and does not have a set-aside designation. Under this contract, Duke University will collaborate with subcontractors Inimmune Corp and the University of North Carolina at...
This is a federal contract award from the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to The Leland Stanford Junior University (Stanford University), a private research institution. The $19,155,153 contract is for a 5-year research program to compare multiple vaccine adjuvants and comprehensively assess the immune responses they induce. The goal is to develop "immune fingerprints" of adjuvants using advanced...
This is a $9,013,936.11 cost-no-fee definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health to the Icahn School of Medicine at Mount Sinai. The contract is part of NIAID's Vaccine Adjuvant Discovery Program and aims to identify novel adjuvant candidates that can be used to enhance the efficacy of human vaccines. The contract has no set-aside designation. Key subcontractors include The Scripps Research Institute,...